By Counterforce Health Team in Brineura (cerliponase alfa) —

How to Get Brineura (cerliponase alfa) Covered by Aetna (CVS Health) in Pennsylvania: Complete PA Guide and Appeal Process

Answer Box: Getting Brineura Covered by Aetna in Pennsylvania

Aetna (CVS Health) requires prior authorization for Brineura (cerliponase alfa) in Pennsylvania with decisions typically within 14 days for standard requests. Key requirements include confirmed CLN2 diagnosis via TPP1 enzyme assay or genetic testing, prescription by a metabolic specialist, and administration at a qualified infusion center. If denied, you can appeal through Aetna's internal process, then Pennsylvania's Independent External Review program within 4 months of your final denial letter—with about 50% of external appeals overturned in favor of patients.

First step today: Call the member services number on your Aetna ID card to verify coverage, deductible status, and request the Brineura precertification form.

Table of Contents

Coverage Requirements at a Glance

Requirement What It Means Where to Find It Source
Prior Authorization Required for all Aetna plan types 2026 Aetna Precertification List Aetna
Diagnosis CLN2 confirmed by TPP1 enzyme assay or genetic testing Aetna Brineura precert form Aetna Policy
Age Requirement ≥3 years (FDA indication expanded in 2024) FDA prescribing information FDA Access Data
Prescriber Metabolic specialist or neurologist Aetna criteria PrescriberPoint Forms
Site of Care Qualified infusion center with ICV capability Provider verification required Aetna Policy
Dosing Maximum 300 mg every 2 weeks FDA label FDA Access Data

Step-by-Step: Fastest Path to Approval

1. Verify Your Coverage (Patient/Family)

Call the member services number on your Aetna ID card. Ask about:

  • Your current deductible and out-of-pocket maximum
  • Whether your plan requires specialty pharmacy (CVS Specialty)
  • If Brineura is on your formulary tier

Timeline: 10-15 minutes
Documents needed: Insurance ID card

2. Gather Diagnostic Documentation (Clinic)

Your medical team needs to compile:

  • TPP1 enzyme deficiency test results
  • Genetic testing showing pathogenic TPP1 mutations
  • CLN2 Clinical Rating Scale scores (baseline and current)
  • Prior treatment history and failures

Timeline: 1-2 weeks
Who does it: Neurologist or genetics team

3. Submit Prior Authorization (Provider)

Download the Aetna Brineura Medication Precertification Request form and submit via:

  • Aetna provider portal (fastest)
  • Fax to specialty pharmacy PA department
  • Express Scripts if your plan uses CVS Caremark

Timeline: Submit within 1 week of gathering docs
Decision timeframe: 14 days standard, 72 hours expedited

4. Follow Up and Track (Clinic Staff)

Monitor submission status through the provider portal. If no response within 10 business days, call to confirm receipt and processing status.

5. Prepare for Possible Denial (Proactive)

While waiting, gather additional supporting evidence:

  • Peer-reviewed studies on CLN2 natural history
  • Letters from infusion center confirming capability
  • Documentation that no alternative treatments exist

Common Denial Reasons & How to Fix Them

Denial Reason How to Overturn Required Documentation
Incomplete CLN2 diagnosis Submit full confirmation TPP1 enzyme assay results and genetic testing
Prescriber not qualified Verify specialist credentials Board certification in pediatric neurology/genetics
Missing motor assessment data Include CLN2 Clinical Rating Scale Baseline and current motor/language scores
Facility not appropriate Confirm ICV infusion capability Hospital accreditation letter for intraventricular access
"Experimental" designation Cite FDA approval FDA prescribing information and no alternatives documentation
Device complications concern Document absence of issues Current clinical notes showing no acute complications
From our advocates: We've seen families succeed by requesting a peer-to-peer review immediately when denied. Having the neurologist speak directly to Aetna's medical director about CLN2's rapid progression and lack of alternatives often resolves coverage within days rather than weeks through formal appeals.

Appeals Playbook for Pennsylvania

Internal Appeal with Aetna (Level 1)

  • Deadline: 60 days from denial date for post-service; 30 days for pre-service
  • How to file: Aetna member portal, phone, or written request
  • Timeline: 30 days for decision (60 days post-service)
  • Required: Copy of denial letter plus new supporting documentation

Key strategy: Request a peer-to-peer review where your neurologist can speak directly with Aetna's medical director about the urgency and medical necessity.

Pennsylvania External Review (Level 2)

Pennsylvania's Independent External Review program offers strong patient protections:

  • Eligibility: Must complete Aetna's internal appeal first
  • Deadline: 4 months from Final Adverse Benefit Determination letter
  • Success rate: Approximately 50% of external appeals favor patients
  • Cost: Free to you (Aetna pays review costs)

How to file:

  1. Submit online at pa.gov external review portal
  2. Email, fax, or mail using PID forms
  3. Include insurance card, denial letter, and medical records

Timeline:

  • Standard review: 45 days from assignment
  • Expedited review: 72 hours (requires physician certification of health risk)
  • You can submit additional information within 15 days of assignment

Medical Necessity Documentation Essentials

For Clinicians: Letter of Medical Necessity Checklist

Your letter should address these key points:

Patient Background:

  • Confirmed CLN2 disease (late-infantile neuronal ceroid lipofuscinosis type 2)
  • TPP1 enzyme deficiency or pathogenic genetic mutations
  • Current age and symptom progression timeline

Clinical Rationale:

  • CLN2 natural history without treatment (wheelchair-bound by age 6, death in mid-teens)
  • Brineura as the only FDA-approved disease-modifying therapy
  • Expected benefit: slowing loss of ambulation and motor function

Treatment Plan:

  • 300 mg intraventricular infusion every 2 weeks
  • Administration at qualified center with neurosurgical support
  • Monitoring plan for device complications and treatment response

Supporting Evidence:

  • Reference FDA clinical trial data (odds ratio 13.1 favoring treatment)
  • Cite lack of alternative disease-modifying therapies
  • Include CLN2 Clinical Rating Scale scores showing decline

Counterforce Health helps streamline this process by generating evidence-backed letters tailored to specific payer requirements, turning denials into targeted appeals that align with Aetna's own coverage policies.

Costs and Patient Support Programs

Financial Assistance Options

BioMarin Patient Support:

  • Co-pay assistance programs for eligible patients
  • Prior authorization support and appeals assistance
  • Access through Brineura.com resources

Foundation Support:

  • Batten Disease Support and Research Association (BDSRA)
  • National Organization for Rare Disorders (NORD)
  • Patient Advocate Foundation

Estimated Costs

  • List price: Approximately $27,000 per biweekly infusion ($702,000 annually)
  • Additional costs: Surgical reservoir placement, infusion center fees, monitoring
  • Insurance coverage: Varies by plan; most cover with prior authorization

When to Escalate to State Regulators

Contact the Pennsylvania Insurance Department if:

  • Aetna delays responses beyond required timelines
  • You suspect bad faith denial practices
  • Appeals are denied without proper medical review

Pennsylvania Insurance Department:

  • Consumer Services: Available through pa.gov
  • External Review Program: Online portal and phone support
  • Complaint filing: For systematic coverage issues

Frequently Asked Questions

How long does Aetna prior authorization take in Pennsylvania? Standard requests: 14 days for most plans, up to 30-45 days for complex cases. Expedited requests (urgent medical need): 72 hours maximum.

What if Brineura is non-formulary on my plan? Request a formulary exception citing FDA approval, lack of alternatives, and medical necessity. Include documentation that CLN2 has no other disease-modifying treatments.

Can I request an expedited appeal? Yes, if there's urgent medical need. Your physician must certify that delays could jeopardize your health. Pennsylvania external reviews can be expedited to 72 hours.

Does step therapy apply to Brineura? Typically no, since there are no alternative disease-modifying therapies for CLN2. If step therapy is required, document that no other treatments address the underlying TPP1 deficiency.

What happens if my external review is approved? Aetna must immediately provide coverage, including retroactive coverage if you paid out-of-pocket during the appeal process.

How do I find a qualified infusion center? Contact your neurologist for referrals to centers experienced with intraventricular infusions. The center must have neurosurgical support and experience with device-related complications.

Counterforce Health specializes in helping patients, clinicians, and specialty pharmacies navigate complex prior authorization processes for rare disease medications. Our platform transforms insurance denials into targeted, evidence-backed appeals by analyzing denial letters, plan policies, and clinical notes to create compelling rebuttals aligned with each payer's specific requirements.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage policies and procedures may change. Always verify current requirements with Aetna and consult with your healthcare providers for medical decisions. For personalized assistance with prior authorizations and appeals, consider consulting with healthcare coverage advocates or legal professionals specializing in insurance matters.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.